Forensic Analysis
Shuttle Pharmaceuticals Holdings, Inc. (SHPH)
A forensic read on Shuttle Pharmaceuticals Holdings, Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
15 · Strong Sell
Rating (0–100)
4
Red flags found
34.6
P / E
$2M
Market cap
Shuttle Pharmaceuticals Holdings, Inc. has pivoted its business to focus on Molecule.ai, an artificial intelligence platform for molecular discovery and early-stage drug development, after winding down its clinical trials for Ropidoxuridine.
The full forensic report — free
🔒Every red flag on SHPH, detailed and traced to the filing
🔒Altman Z distress & Beneish M earnings-quality screens
🔒Calibrated 12-month price forecast + reverse-DCF
🔒Earnings-quality & capital-allocation forensics
No credit card · informational only, not investment advice
← Browse all forensic stock analyses
Data from SEC EDGAR public filings. Forensic signals flag probability, not certainty.